Biosimilar Manufacturers Face Supply Chain Challenges Leading to Delays and Increased Costs

Biosimilar manufacturers are facing significant challenges due to supply chain complexities, which can lead to delays, increased costs, and lost revenue, according to a recent article published by DrugPatentWatch. The article identifies a lack of standardization and transparency within the biosimilar supply chain as a critical issue impacting the industry. The DrugPatentWatch article emphasizes the intricacies of the biosimilar supply chain. These complexities are causing inefficiencies that affect biosimilar businesses. To address these challenges, the article suggests manufacturers explore strategies to overcome supply chain bottlenecks and improve overall efficiency.

Newsflash | Powered by GeneOnline AI
Date: April 14, 2025

Related posts:

Study Reveals Cognitive Decline Linked to Low-Normal Vitamin B12 Levels Roger Perlmutter’s New Biotech Startup Secures $350 Million in Funding Breakthrough in Cancer Vaccine Development Enhances Effectiveness and Reach Anne Wojcicki’s Bold Move to Reclaim 23andMe Sparks Debate in Biotech Industry

Author

Mark Chiang

紐約 NYU Computer Science 碩士 紐澤西 UMDNJ Biomedical Informatics 博士 中研院博士後 台灣大學博士後